MHC-Ig Induces Memory T Cell Formation in Vivo and Inhibits Tumour Growth

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2014 Dec 16

PMID 25505552

Citations 3

Authors

Christian Schutz

Alessia Zoso

Shiwen Peng

Jonathon D Bennett

Jonathan P Schneck

Mathias Oelke

Affiliations

Soon will be listed here.

Abstract

Induction of a T cell mediated immune response is critical for the eradication of viral infections and tumours. Soluble peptide-loaded major histocompatibility complex-Ig ((pep-)MHC-Ig) have been shown to bind their cognate ligands, T cell receptor, with high affinity, and are successfully used to visualize antigen-specific T cells. Furthermore, immobilized (pep-)MHC-Ig can activate and expand antigen-specific T cells in vitro and in vivo. In this study, we investigate the use of (pep-)MHC-Ig as a potential strategy to modulate antigen specific T cell immune responses in vivo. (SIY-)K(b)-Ig immunization, together with the pre-activation by an anti-CD40 monoclonal antibody, is able to stimulate a strong expansion of adoptively transferred 2C transgenic T cells and the formation of long term antigen-specific memory T cells. In addition, mechanistic studies show that the (pep-)MHC-Ig molecules directly activate T cells in vivo without requiring uptake and reprocessing by antigen-presenting cells. Furthermore, B6 mice immunized with (pep-)MHC-Ig molecules inhibit tumour growth in a B16-SIY melanoma prevention model. Thus, soluble (pep-)MHC-Ig molecules represent a powerful tool for active immunotherapy.

Citing Articles

In Vivo Stimulation of Therapeutic Antigen-Specific T Cells in an Artificial Lymph Node Matrix.

Livingston N, Hickey J, Sim H, Salathe S, Choy J, Kong J Adv Mater. 2024; 36(23):e2310043.

PMID: 38358310 PMC: 11161322. DOI: 10.1002/adma.202310043.

Commensal bacteria stimulate antitumor responses via T cell cross-reactivity.

Bessell C, Isser A, Havel J, Lee S, Bell D, Hickey J JCI Insight. 2020; 5(8).

PMID: 32324171 PMC: 7205429. DOI: 10.1172/jci.insight.135597.

Soluble MHC class I complexes for targeted immunotherapy.

Schappert A, Schneck J, Suarez L, Oelke M, Schutz C Life Sci. 2018; 209:255-258.

PMID: 30102903 PMC: 6149538. DOI: 10.1016/j.lfs.2018.08.023.

References

Wu Y, Liu Y . Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses. Curr Biol. 1994; 4(6):499-505. DOI: 10.1016/s0960-9822(00)00110-x. View

Bevan M . Helping the CD8(+) T-cell response. Nat Rev Immunol. 2004; 4(8):595-602. DOI: 10.1038/nri1413. View

Janssen E, Lemmens E, Wolfe T, Christen U, von Herrath M, Schoenberger S . CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003; 421(6925):852-6. DOI: 10.1038/nature01441. View

Greten T, Schneck J . Development and use of multimeric major histocompatibility complex molecules. Clin Diagn Lab Immunol. 2002; 9(2):216-20. PMC: 119966. DOI: 10.1128/cdli.9.2.216-220.2002. View

Goldstein J, Mostowsky H, Tung J, Hon H, Brunswick M, Kozlowski S . Naive alloreactive CD8 T cells are activated by purified major histocompatibility complex class I and antigenic peptide. Eur J Immunol. 1997; 27(4):871-8. DOI: 10.1002/eji.1830270411. View

Greten T, Korangy F, Neumann G, Wedemeyer H, Schlote K, Heller A . Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J Immunol Methods. 2002; 271(1-2):125-35. DOI: 10.1016/s0022-1759(02)00346-0. View

Goldstein J, Chen T, Brunswick M, Mostowsky H, Kozlowski S . Purified MHC class I and peptide complexes activate naive CD8+ T cells independently of the CD28/B7 and LFA-1/ICAM-1 costimulatory interactions. J Immunol. 1998; 160(7):3180-7. View

von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, Debey S . CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2005; 107(7):2786-9. PMC: 1895368. DOI: 10.1182/blood-2004-01-0113. View

Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393(6684):478-80. DOI: 10.1038/30996. View

10.

Harty J, Badovinac V . Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol. 2008; 8(2):107-19. DOI: 10.1038/nri2251. View

11.

Slansky J, Rattis F, Boyd L, Fahmy T, Jaffee E, Schneck J . Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 2000; 13(4):529-38. DOI: 10.1016/s1074-7613(00)00052-2. View

12.

Carey B, DeLay M, Strasser J, Chalk C, Dudley-McClain K, Milligan G . A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clin Immunol. 2005; 116(1):65-76. DOI: 10.1016/j.clim.2005.02.013. View

13.

Salerno E, Shea S, Olson W, Petroni G, Smolkin M, McSkimming C . Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother. 2013; 62(7):1149-59. PMC: 3813823. DOI: 10.1007/s00262-013-1435-5. View

14.

Lebowitz M, OHerrin S, Hamad A, Fahmy T, Marguet D, Barnes N . Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cell Immunol. 1999; 192(2):175-84. DOI: 10.1006/cimm.1999.1441. View

15.

Fried A, Berg M, Sharma B, Bonde S, Zavazava N . Recombinant dimeric MHC antigens protect cardiac allografts from rejection and visualize alloreactive T cells. J Leukoc Biol. 2005; 78(3):595-604. DOI: 10.1189/jlb.0205078. View

16.

Bourgeois C, Rocha B, Tanchot C . A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002; 297(5589):2060-3. DOI: 10.1126/science.1072615. View

17.

Sun S, Cai Z, Langlade-Demoyen P, Kosaka H, Brunmark A, Jackson M . Dual function of Drosophila cells as APCs for naive CD8+ T cells: implications for tumor immunotherapy. Immunity. 1996; 4(6):555-64. DOI: 10.1016/s1074-7613(00)80482-3. View

18.

Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina M, Huang X . Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med. 2013; 19(4):465-72. PMC: 3618499. DOI: 10.1038/nm.3105. View

19.

Maile R, Wang B, Schooler W, Meyer A, Collins E, Frelinger J . Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol. 2001; 167(7):3708-14. DOI: 10.4049/jimmunol.167.7.3708. View

20.

Savage P, Millrain M, Dimakou S, Stebbing J, Dyson J . Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumour Biol. 2007; 28(2):70-6. DOI: 10.1159/000099152. View